VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer Meeting Abstract
| Authors: | Vergote, I. B.; Pérez Fidalgo, A.; Hamilton, E.; Valabrega, G.; Van Gorp, T.; Sehouli, J.; Cibula, D.; Levy, T.; Welch, S.; Richardson, D. L.; Guerra Alia, E. M.; Scambia, G.; Henry, S.; Wimberger, P.; Miller, D.; Martínez, J.; Monk, B. J.; Shacham, S.; Mirza, M. R.; Makker, V. |
| Abstract Title: | VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer |
| Meeting Title: | ESMO Virtual Plenary: March 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | 4 |
| Meeting Dates: | 2022 Mar 17-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-04-01 |
| Start Page: | 448 |
| End Page: | 450 |
| Language: | English |
| ACCESSION: | WOS:000797530500001 |
| DOI: | 10.1016/j.annonc.2022.02.223 |
| PROVIDER: | wos |
| Notes: | Meeting abstract -- Source: Wos |
